Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan W Friedberg

Showing results (151-160 of 300) with videos related to

Pageof 30
Sort By:
Archives of Pathology & Laboratory Medicine|December 7, 2023
T-Cell-Rich Hodgkin Lymphoma With Features of Classic Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Borderline Category With Overlapping Morphologic and Immunophenotypic FeaturesSiba El Hussein, Hong Fang, Fatima Zahra Jelloul, et al.
British Journal of Haematology|June 13, 2002
Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphomaJonathan W Friedberg, Donna Neuberg, John G Gribben, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2013
Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomasJonathan W Friedberg, Daruka Mahadevan, Erin Cebula, et al.
Blood|October 18, 2017
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HLJonathan W Friedberg, Andres Forero-Torres, Rodolfo E Bordoni, et al.
Blood|March 23, 2017
Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapyAjay K Gopal, Brad S Kahl, Christopher R Flowers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2008
Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer NetworkAnn S LaCasce, Michelle E Kho, Jonathan W Friedberg, et al.
Leukemia & Lymphoma|April 23, 2004
Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphomaJennifer R Brown, Guylaine Gaudet, Jonathan W Friedberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 30, 2011
Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic eraSarah F Keller, Jennifer L Kelly, Elizabeth Sensenig, et al.
Hematological Oncology|April 6, 2017
Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015Randy D Gascoyne, Bertrand Nadel, Laura Pasqualucci, et al.
The Lancet. Haematology|February 4, 2018
R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre studyPaul M Barr, Hongli Li, W Richard Burack, et al.
Pageof 30

Showing results (151-160 of 300) with videos related to

Sort By:
Pageof 30
Archives of Pathology & Laboratory Medicine|December 7, 2023
T-Cell-Rich Hodgkin Lymphoma With Features of Classic Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Borderline Category With Overlapping Morphologic and Immunophenotypic FeaturesSiba El Hussein, Hong Fang, Fatima Zahra Jelloul, et al.
British Journal of Haematology|June 13, 2002
Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphomaJonathan W Friedberg, Donna Neuberg, John G Gribben, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2013
Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomasJonathan W Friedberg, Daruka Mahadevan, Erin Cebula, et al.
Blood|October 18, 2017
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HLJonathan W Friedberg, Andres Forero-Torres, Rodolfo E Bordoni, et al.
Blood|March 23, 2017
Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapyAjay K Gopal, Brad S Kahl, Christopher R Flowers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2008
Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer NetworkAnn S LaCasce, Michelle E Kho, Jonathan W Friedberg, et al.
Leukemia & Lymphoma|April 23, 2004
Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphomaJennifer R Brown, Guylaine Gaudet, Jonathan W Friedberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 30, 2011
Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic eraSarah F Keller, Jennifer L Kelly, Elizabeth Sensenig, et al.
Hematological Oncology|April 6, 2017
Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015Randy D Gascoyne, Bertrand Nadel, Laura Pasqualucci, et al.
The Lancet. Haematology|February 4, 2018
R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre studyPaul M Barr, Hongli Li, W Richard Burack, et al.
Pageof 30